<DOC>
	<DOCNO>NCT02590588</DOCNO>
	<brief_summary>The investigator expect enroll 15 participant relapsed refractory IgM-associated AL amyloidosis onto Phase II clinical trial . Idelalisib self-administered orally dose 100 mg twice daily ( may increase 150 mg ( one tablet ) twice daily 3 month investigator discretion ) . Participants treat disease progression , unacceptable toxicity , decision withdraw trial . Disease evaluation perform every three month disease progression .</brief_summary>
	<brief_title>Idelalisib Immunoglobulin M ( IgM ) -Associated Primary ( AL ) Amyloidosis</brief_title>
	<detailed_description>This study include use Idelalisib treat previously treat patient IgM-associated AL Amyloidosis Boston Medical Center . Boston Medical Center internationally recognize leader amyloidosis research patient care activity multidisciplinary Amyloid Center Boston University . The problematic cell form AL amyloidosis share similarities multiple myeloma . However , small subset AL Amyloidosis patient IgM paraprotein , cell typically relate lymphoplasmacytic lymphoma Waldenstrom 's macroglobulinemia . Because clonal CD20+ lymphoplasmacytic cell usually responsible IgM paraproteins , treatment paradigm base Waldenstrom 's macroglobulinemia ( WM ) may appropriate myeloma-based strategy . Idelalisib show active well tolerated patient relapsed/refractory non-Hodgkin lymphoma include chronic lymphocytic lymphoma , lymphoplasmacytic lymphoma without Waldenström 's macroglobulinemia ( WM ) . The side effect profile idelalisib merges well know predisposition toxicity amyloidosis patient . The investigator expect enroll 15 participant IgM-associated AL amyloidosis onto Phase II clinical trial . Idelalisib self-administered orally dose 100 mg ( 1 tablet ) twice daily ( may escalate 150 mg ( one tablet ) twice daily 3 month investigator discretion ) . Participants treat disease progression , unacceptable toxicity , decision withdraw trial . Disease evaluation perform every three month disease progression .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>3.1.1 IgM paraprotein identify serum immunofixation electrophoresis OR light chainrestricted CD20+ lymphoplasmacytic population biopsy bone marrow lymph node ( identify H &amp; E/immunohistochemistry flow cytometry ) OR positive myeloid differentiation primary response gene 88 ( MYD88L265P ) OR CXCR4WHIM mutation submit sample 3.1.2 Biopsyproven relapse refractory AL amyloidosis 3.1.3 Age ≥ 18 year 3.1.4 Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 ( see Appendix A . ) 3.1.5 Difference serum free light chain ( FLC ) &gt; 30 mg/L quantifiable IgM paraprotein &gt; 0.5 g/L 3.1.6 Participants must normal organ marrow function define : Absolute neutrophil count &gt; 1,000/mm3 Platelets &gt; 50,000/mm3 3.1.7 Ability understand willingness sign write informed consent document . 3.2.1 Previous treatment idelalisib 3.2.2 Glomerular filtration rate ( GFR ) &lt; 15 ml/min 3.2.3 Cardiac biomarker Stage III disease determine Btype natriuretic peptide ( BNP ) &gt; 100 pg/mL TroponinI &gt; 0.1 ng/mL ( Girnius 2014 ) 3.2.4 ALT/AST value &gt; 2.5x ULN , Bilirubin &gt; 1.5 upper limit normal ( ULN ) 3.2.5 Central nervous system ( CNS ) malignancy active malignancy 3.2.6 Lactating pregnant woman 3.2.7 Exposure another investigational drug within 4 week prior start study treatment 3.2.8 Ongoing alcohol drug addiction determine investigator 3.2.9 Amyloiddirected therapy within past 28 day 3.2.10 History Human Immunodeficiency Virus ( HIV ) , active Hepatitis B Virus ( HBV ) ( assess positive Hepatitis B polymerase chain reaction assay ( PCR ) HepB Surface Antigen ) , and/or Hepatitis C Virus ( HCV ) infection 3.2.11 ( 11,14 ) translocation identify bone marrow cytogenetics FISH 3.2.12 Known lytic bone lesion 3.2.13 Positive CMV PCR 3.2.14 Previously untreated AL amyloidosis ( Newly diagnose ) 3.2.15 Unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>IgM-associated AL amyloidosis</keyword>
</DOC>